Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Cyclacel Pharmaceuti (NQ: CYCCP )

7.450 USD +0.070 (+0.95%)
Official Closing Price Updated: 4:00 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 500
Open 7.600
Bid (Size) 7.320 (2)
Ask (Size) 8.210 (1)
Prev. Close 7.380
Today's Range 7.450 - 8.000
52wk Range 4.810 - 9.350
Shares Outstanding 335,273
Dividend Yield 8.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
Conference Call Scheduled February 25, 2021 at 4:30 p.m. EDT 
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results
From GlobeNewswire News Releases

Performance

YTD
+5.97%
+5.97%
1 Month
-6.88%
-6.88%
3 Month
+25.00%
+25.00%
6 Month
+39.12%
+39.12%
1 Year
+21.14%
+21.14%

More News

Read More
Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals Announces That Brian Schwartz, M.D. Was Elected to Its Board of Directors
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals to Release Third Quarter Financial Results
From GlobeNewswire News Releases
Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.